Page last updated: 2024-11-03

propranolol and Ache

propranolol has been researched along with Ache in 80 studies

Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

Research Excerpts

ExcerptRelevanceReference
" In intention-to-treat and per-protocol analyses, patients randomized to propranolol had worse pain scores on study days 5 to 19."9.20Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury. ( Bangdiwala, SI; Bortsov, AV; Cairns, BA; Haith, LR; Halawa, OI; Holmes, JH; Hoskins, JM; Hwang, J; Jones, SW; Jordan, MH; McLean, SA; Orrey, DC; Platts-Mills, TF; Roane, BR; Shupp, JW, 2015)
"Propranolol significantly decreased perceived intensity of heat pain stimuli but only in participants with small propranolol-induced blood pressure decreases."9.17Effects of intravenous propranolol on heat pain sensitivity in healthy men. ( Abulhasan, YB; Alhujairi, M; Balderi, T; Carli, F; Kim, DJ; Koeva, V; Schweinhardt, P, 2013)
"The number of patients reporting a reduction in pain intensity rating was greater during propranolol treatment (P=0."9.14Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. ( Diatchenko, L; Lim, PF; Maixner, W; McLean, SA; Slade, GD; Smith, SB; Tchivileva, IE, 2010)
"Serum propranolol concentration, elimination t 1/2, and protein binding were studied after a combined intravenous/oral regimen in 20 subjects with myocardial infarction (MI) and 15 with chest pain (CP)."7.67Propranolol disposition after acute myocardial infarction. ( Norris, RM; Paxton, JW, 1984)
"Propranolol was administered intravenously to 12 patients with presumed acute myocardial infarction in the attempt to limit infarct size."7.66Intravenous propranolol therapy for acute myocardial infarction in man: hemodynamic and serial creatine kinase assessment. ( Cairns, JA; Klassen, GA, 1981)
" In intention-to-treat and per-protocol analyses, patients randomized to propranolol had worse pain scores on study days 5 to 19."5.20Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury. ( Bangdiwala, SI; Bortsov, AV; Cairns, BA; Haith, LR; Halawa, OI; Holmes, JH; Hoskins, JM; Hwang, J; Jones, SW; Jordan, MH; McLean, SA; Orrey, DC; Platts-Mills, TF; Roane, BR; Shupp, JW, 2015)
"Propranolol significantly decreased perceived intensity of heat pain stimuli but only in participants with small propranolol-induced blood pressure decreases."5.17Effects of intravenous propranolol on heat pain sensitivity in healthy men. ( Abulhasan, YB; Alhujairi, M; Balderi, T; Carli, F; Kim, DJ; Koeva, V; Schweinhardt, P, 2013)
"The number of patients reporting a reduction in pain intensity rating was greater during propranolol treatment (P=0."5.14Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. ( Diatchenko, L; Lim, PF; Maixner, W; McLean, SA; Slade, GD; Smith, SB; Tchivileva, IE, 2010)
"We studied usefulness of iontophoresis on pain relief using several Ca channel blockers, propranolol and guanethidine."3.68[Influence of calcium channel blockers and beta-blockers on pain relief with iontophoresis]. ( Honda, N; Ikebe, H; Miyagawa, A; Mizutani, A; Sendaya, K; Taniguchi, K; Yoshitake, S, 1992)
"Serum propranolol concentration, elimination t 1/2, and protein binding were studied after a combined intravenous/oral regimen in 20 subjects with myocardial infarction (MI) and 15 with chest pain (CP)."3.67Propranolol disposition after acute myocardial infarction. ( Norris, RM; Paxton, JW, 1984)
"Propranolol was administered intravenously to 12 patients with presumed acute myocardial infarction in the attempt to limit infarct size."3.66Intravenous propranolol therapy for acute myocardial infarction in man: hemodynamic and serial creatine kinase assessment. ( Cairns, JA; Klassen, GA, 1981)
" Mental stimulation or isoproterenol, and, respectively, pain or beta blockade induce changes of the repolarization phase divergent from steady state."3.65Stress-induced and sympathetically-mediated electrocardiographic and circulatory variations in the primary hyperkinetic heart syndrome. ( Fiorentini, C; Guazzi, M; Magrini, F; Olivari, MT; Polese, A, 1975)
"In 31 patients with at least 3 migraine attacks per month the prophylactic effect of tolfenamic acid 300 mg/day, propranolol 120 mg/day, and placebo was compared in a randomized double-blind cross-over study."2.66Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. ( Christiansen, LV; Mikkelsen, B; Pedersen, KK, 1986)
"Propranolol pretreatment had no impact on analgesia from oral hydromorphone."1.72CYP2D in the brain impacts oral hydrocodone analgesia in vivo. ( Miksys, S; Novalen, M; Richards, J; Tyndale, RF, 2022)
"Pretreatment with propranolol or nor-BNI prior to restraint stress prevented both transient cutaneous allodynia and priming, demonstrated by a lack of umbellulone-induced cutaneous allodynia."1.62A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. ( Chessell, IP; Dodick, DW; Kopruszinski, CM; Navratilova, E; Porreca, F; Swiokla, J, 2021)
"Propranolol has anti-inflammatory effects that contribute to its antinociceptive action in the TMJ of females."1.48Anti-inflammatory effects of propranolol in the temporomandibular joint of female rats and its contribution to antinociceptive action. ( Dias, EV; Parada, CA; Sartori, CR; Tambeli, CH; Teixeira, JM; Zanelatto, FB, 2018)
"Erythromelalgia is a rare clinical syndrome characterized by erythema, increased temperature, and severe burning pain that can be aggravated by warmth or relieved by cold."1.42Erythromelalgia with a linear pattern in a 12-year-old girl. ( Choi, JY; Eun, LY; Huh, S; Jung, JW; Jung, MK, 2015)
"Propranolol is a non-selective β adrenergic receptor blocker which antagonises the anti-inflammatory effect of non-steroidal anti-inflammatory drugs via the β1 and β2 adrenergic receptors."1.37Effects of epinephrine and cortisol on the analgesic activity of metyrosine in rats. ( Akcay, F; Albayrak, Y; Karatay, S; Polat, B; Saglam, MB; Suleyman, H; Uslu, T; Yildirim, K, 2011)
"These arrhythmias occurred also with a short latency (mean 8."1.32Ventricular arrhythmias triggered by alerting stimuli in conscious rabbits pre-treated with dofetilide. ( Blessing, WW; De Pasquale, CG; Nalivaiko, E, 2004)
"The prognosis of treated hypochondriasis is good in a substantial proportion of patients."1.27Functional somatic symptoms and hypochondriasis. A survey of empirical studies. ( Kellner, R, 1985)
"The hyperthyroidism is self-limiting and should be treated conservatively."1.26Thyrotoxicosis with painless thyroiditis. ( Daly, R; Woolf, PD, 1976)
"The responsiveness of both migraine headaches and carotidynia to similar drugs suggests a common pathophysiologic mechanism."1.26Carotidynia. ( Prusiner, S; Raskin, NH, 1977)

Research

Studies (80)

TimeframeStudies, this research(%)All Research%
pre-199050 (62.50)18.7374
1990's9 (11.25)18.2507
2000's4 (5.00)29.6817
2010's11 (13.75)24.3611
2020's6 (7.50)2.80

Authors

AuthorsStudies
Arguelles, N1
Richards, J2
El-Sherbeni, AA1
Miksys, S2
Tyndale, RF2
Günay, Ç1
Edem, P1
Hız-Kurul, AS1
Yaşar, E1
Yiş, U1
Cairns, BE1
Novalen, M1
Brignardello-Petersen, R1
Kopruszinski, CM1
Navratilova, E1
Swiokla, J1
Dodick, DW1
Chessell, IP1
Porreca, F1
Zanelatto, FB1
Dias, EV1
Teixeira, JM1
Sartori, CR1
Parada, CA1
Tambeli, CH1
Hernández, CR1
Loza, SM1
López, RL1
Del Mar García Romero, M1
Kurauchi, Y1
Haruta, M1
Tanaka, R1
Sasagawa, K1
Ohta, J1
Hisatsune, A1
Seki, T1
Katsuki, H1
Tzeng, JI1
Pan, HJ1
Liu, KS1
Chen, YW1
Chen, YC1
Wang, JJ1
Orrey, DC1
Halawa, OI1
Bortsov, AV1
Shupp, JW1
Jones, SW1
Haith, LR1
Hoskins, JM1
Jordan, MH1
Bangdiwala, SI1
Roane, BR1
Platts-Mills, TF1
Holmes, JH1
Hwang, J1
Cairns, BA1
McLean, SA2
Kline, RH1
Exposto, FG1
O'Buckley, SC1
Westlund, KN1
Nackley, AG1
Huh, S1
Jung, MK1
Eun, LY1
Jung, JW1
Choi, JY1
Light, KC1
Bragdon, EE1
Grewen, KM1
Brownley, KA1
Girdler, SS1
Maixner, W2
Tchivileva, IE1
Lim, PF1
Smith, SB1
Slade, GD1
Diatchenko, L1
Cadirci, E1
Suleyman, H2
Hacimuftuoglu, A1
Halici, Z1
Akcay, F2
Albayrak, Y1
Saglam, MB1
Yildirim, K1
Karatay, S1
Polat, B1
Uslu, T1
Schweinhardt, P1
Abulhasan, YB1
Koeva, V1
Balderi, T1
Kim, DJ1
Alhujairi, M1
Carli, F1
Nalivaiko, E1
De Pasquale, CG1
Blessing, WW1
Ferreira, J1
Trichês, KM1
Medeiros, R1
Calixto, JB1
Meerson, FZ1
Medvedev, LN1
Golubeva, LIu1
Ustinova, EE1
Kehlet, H1
Sicuteri, F1
Pantely, GA1
Kloster, FE1
Morris, CD1
Paxton, JW1
Norris, RM1
Catania, A1
Caimi, G1
Jay, GW1
Renelli, D1
Mead, T1
Ahmad, S1
Areskog, NH1
Bailey, RR1
Saavedra, JM1
Hollenberg, M1
Budge, WR1
Wisneski, JA1
Gertz, EW1
Nixon, JV1
Hillert, MC1
Shapiro, W1
Smitherman, TC1
Carstens, E1
Zimmermann, M1
Gay, JL1
Nash, ML1
Kunkes, SH1
Pichard, AD1
Smith, H1
Gorlin, R1
Herman, MV1
Kupersmith, J1
Cairns, JA1
Klassen, GA1
Koley, J1
Basak, AK1
Das, M1
Sinha, S1
Koley, B1
Doak, GJ1
Sawynok, J1
Miao, FJ1
Levine, JD1
Ernberg, M1
Lundeberg, T1
Kopp, S1
Woolf, PD1
Daly, R1
Madias, JE1
Raskin, NH1
Prusiner, S1
Kopriva, CJ1
Guinazu, A1
Barash, PG1
Plotnick, GD1
Rainsford, KD1
Oster, KA1
Ross, DJ1
Barg, IA1
Lisnianskaia, RIa1
Novikov, VT1
Al'perovich, BR1
Aranda, JM1
Befeler, B1
El-Sherif, N1
Castellanos, A1
Lazzara, R1
Guazzi, M2
Fiorentini, C2
Polese, A2
Magrini, F2
Olivari, MT1
Peng, YI1
Liu, HJ1
Guo, L1
Fu, TC1
Miyagawa, A1
Taniguchi, K1
Sendaya, K1
Mizutani, A1
Yoshitake, S1
Ikebe, H1
Honda, N1
Olsen, UB1
Lund, A1
Foo, H1
Westbrook, RF1
Cunha, FQ1
Lorenzetti, BB1
Poole, S1
Ferreira, SH1
Miller, JF1
Proudfit, HK1
Albus, M1
Zellner, A1
Bondy, B1
Müller-Spahn, F1
Engel, R1
Ackenheil, M1
Wang, YJ1
Wang, SK1
Hough, LB1
Glick, SD1
Su, K1
Kellner, R1
Fujiwara, R1
Orita, K1
Bragin, EO1
Nakamura, M1
Lico, MC1
Mikkelsen, B1
Pedersen, KK1
Christiansen, LV1
Yu, GD1
Chen, JS1
Yin, WP1
Yin, QZ1
Zeng, WY1
Kassirer, JP1
Kopelman, RI1
Dean, GA1
Guidobono, F1
Netti, C1
Sibilia, V1
Olgiati, VR1
Pecile, A1
Bory, M1
Karila, P1
Sainsous, J1
Cohen, S1
Djiane, P1
Paulin, R1
Serradimigni, A1
Boakes, AJ1
Prichard, BN1
Lukasik, S1
Wrabec, K1
Nowosad, H1
Vorherr, H1
Yasue, H1
Touyama, M1
Shimamoto, M1
Kato, H1
Tanaka, S1
Hanazono, N1
Shimoyama, S1
Ando, Y1
Hilty-Tammivaara, R1
Cullhed, I1
Miasnikov, LA1
Krasnikov, IuA1
Nicotero, JA1
Beamer, V1
Moutsos, SE1
Shapiro, AP1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Analgesic Effects of Perioperative Propranolol Administration for Spine Surgery[NCT04421209]Phase 20 participants (Actual)Interventional2020-12-31Withdrawn (stopped due to No funding source)
Contribution of COMT Haplotypes in Propranolol Analgesic Efficacy for Treating Post-surgical Pain After Laparoscopic Hemicolectomy[NCT02511483]Phase 210 participants (Actual)Interventional2015-05-18Terminated (stopped due to Difficulty with recruitment)
The Effect of Sympathetic Dysfunction on Muscle Spindle Activity in Patients With Fibromyalgia Syndrome[NCT05704374]36 participants (Anticipated)Interventional2023-11-02Not yet recruiting
Effect of COMT (Catecholamine-O-methyltransferase) Genetic Polymorphisms on Response to Propranolol Therapy in Temporomandibular Disorder[NCT02437383]Phase 2200 participants (Actual)Interventional2015-08-20Completed
Genetic Variants Associated With the Occurrence of Localized Low Back Pain or Low Back Pain With Widespread Pain Symptoms, and Their Response to Treatment With Duloxetine or Propranolol[NCT03364075]Phase 210 participants (Actual)Interventional2017-09-01Terminated (stopped due to Recruitment issue)
The Serotonin Receptor Type 3 Antagonist Granisetron as a New Treatment Approach for Patients With Chronic Myofascial Pain in the Orofacial Muscles[NCT02230371]Phase 440 participants (Actual)Interventional2007-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Diastolic Blood Pressure After 9 Weeks of Treatment

Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionmm Hg (Least Squares Mean)
Propranolol ER-3.3
Placebo1.0

Change in Heart Rate After 9 Weeks of Treatment

Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionbeats per minute (Least Squares Mean)
Propranolol ER-3.9
Placebo1.5

Change in Maximum Assisted Jaw Opening After 9 Weeks of Treatment

Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionmm (Least Squares Mean)
Propranolol ER-0.3
Placebo-0.8

Change in Maximum Unassisted Jaw Opening After 9 Weeks of Treatment

Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionmm (Least Squares Mean)
Propranolol ER-0.9
Placebo-1.2

Change in Pain-free Jaw Opening After 9 Weeks of Treatment

Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionmm (Least Squares Mean)
Propranolol ER4.5
Placebo1.4

Change in Pressure Pain Threshold at Lateral Epicondyle After 9 Weeks of Treatment

Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of lateral epicondyle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

InterventionkPa (Least Squares Mean)
Propranolol ER41.4
Placebo22.7

Change in Pressure Pain Threshold at Masseter Muscle After 9 Weeks of Treatment

Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of masseter muscle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/- 7)

InterventionkPa (Least Squares Mean)
Propranolol ER38.3
Placebo29.3

Change in Pressure Pain Threshold at Temporalis Muscle After 9 Weeks of Treatment

Pressure values, measured in kilopascals (kPa), from up to 5 experimental pressure stimuli, bilaterally applied to the area of temporalis muscle, are averaged to obtain a single pressure pain threshold value per anatomical site. The range is 0-500 kPa and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

InterventionkPa (Least Squares Mean)
Propranolol ER41.8
Placebo38.4

Change in Pressure Pain Threshold at Temporomandibular Joint After 9 Weeks of Treatment

Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of temporomandibular joint, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

InterventionkPa (Least Squares Mean)
Propranolol ER36.8
Placebo25.3

Change in Pressure Pain Threshold at Trapezius Muscle After 9 Weeks of Treatment

Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of trapezius muscle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

InterventionkPa (Least Squares Mean)
Propranolol ER64.1
Placebo63.3

Change in Systolic Blood Pressure After 9 Weeks of Treatment

Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionmm Hg (Least Squares Mean)
Propranolol ER-3.6
Placebo1.3

Change in the Headache Impact Test (HIT-6) Global Score After 9 Weeks of Treatment

"The HIT-6 contains 6 items and assesses headache-related disability by the frequency of daily activity limitations ranging from never to always. The 6 item scores are summed to yield a global score ranging from 36 to 78. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-5.1
Placebo-3.1

Change in the Hospital Anxiety and Depression Scale (HADS) Anxiety Score After 9 Weeks of Treatment

"The HADS is a 14-item assessment of anxiety (7 items) and depression (7 items) using the relative frequency of symptoms over the past week, rated on a 4-point scale ranging from 0 = not at all to 3 = very often indeed. Responses are summed to provide separate scores for anxiety and depression with a range from 0 to 21. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-1.3
Placebo-0.7

Change in the Hospital Anxiety and Depression Scale (HADS) Depression Score After 9 Weeks of Treatment

"The HADS is a 14-item assessment of anxiety (7 items) and depression (7 items) using the relative frequency of symptoms over the past week, rated on a 4-point scale ranging from 0 = not at all to 3 = very often indeed. Responses are summed to provide separate scores for anxiety and depression with a range from 0 to 21. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-1.0
Placebo-0.6

Change in the Jaw Functional Limitation Scale (JFLS) Global Score After 9 Weeks of Treatment

"The JFLS contains 20 items that measure limitations across mastication, vertical jaw mobility, and verbal/emotional expression rated on a 0-10 scale where 0 = no limitation and 10 = severe limitation. The Global Score is computed as the mean response for all items and ranges from 0 to 10. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-1.1
Placebo-0.8

Change in the Perceived Stress Scale (PSS) Global Score After 9 Weeks of Treatment

"The PSS assesses the frequency of 14 sources of stress on a scale from 0 = never to 4 = very often. The item scores are summed to yield a global score ranging from 0 to 56. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-2.6
Placebo-1.9

Change in the Pittsburgh Sleep Quality Index (PSQI) Global Score After 9 Weeks of Treatment

The PSQI has 19 items grouped into 7 component scores, each weighted equally on a 0-3 scale, The 7 component scores are summed to yield a global PSQI score, which has a range of 0-21. A higher score means a worse outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-0.7
Placebo-1.0

Change in the SF-12 Health Survey v2 (SF-12v2) Mental Component Summary (MCS) After 9 Weeks of Treatment

"The SF-12v2 contains 7 questions assessing 8 domains of functioning and well-being rated from: excellent to poor (for general health); yes, limited a lot to no, not limited at all (for functional level); and all of the time to none of the time (for emotional state). These 8 domains can be further summarized into a physical component summary (PCS) and a mental component summary (MCS). The range for each component is 0-100 and a higher score means a better outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER3.6
Placebo2.8

Change in the SF-12 Health Survey v2 (SF-12v2) Physical Component Summary (PCS) After 9 Weeks of Treatment

"The SF-12v2 contains 7 questions assessing 8 domains of functioning and well-being rated from: excellent to poor (for general health); yes, limited a lot to no, not limited at all (for functional level); and all of the time to none of the time (for emotional state). These 8 domains can be further summarized into a physical component summary (PCS) and a mental component summary (MCS). summary (MCS). The range for each component is 0-100 and a higher score means a better outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER1.2
Placebo0.3

Change in the SF-McGill Pain Questionnaire Affective Component After 9 Weeks of Treatment

"The SF-McGill Pain Questionnaire contains 4 affective descriptors rated on a 0-3 scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. The item scores are summed to yield a total score ranging from 0 to 12. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-2.9
Placebo-3.1

Change in the SF-McGill Pain Questionnaire Present Facial Pain Intensity After 9 Weeks of Treatment

"Self-reported present intensity of facial pain at the moment of assessment scored on a descriptive scale where 1 = no pain' and 6 = excruciating pain. A higher score means worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-0.9
Placebo-0.7

Change in the SF-McGill Pain Questionnaire Sensory Component After 9 Weeks of Treatment

"The SF-McGill Pain Questionnaire contains 11 sensory descriptors rated on a 0-3 scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. The item scores are summed to yield a total score ranging from 0 to 33. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-1.9
Placebo-1.6

Change in the SF-McGill Pain Questionnaire Weekly Average Facial Pain Duration After 9 Weeks of Treatment

"Self-reported average facial pain duration for the last week scored on 0-100 percentage scale where percent = percent of waking day you had facial pain. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-23.6
Placebo-21.6

Change in the SF-McGill Pain Questionnaire Weekly Average Facial Pain Intensity After 9 Weeks of Treatment

"Self-reported average facial pain intensity for the last week scored on 0-100 numerical rating scale where 0 = no pain and 100 = the most intense pain imaginable. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-18.2
Placebo-15.8

Change in the SF-McGill Pain Questionnaire Weekly Fatigue After 9 Weeks of Treatment

"Self-reported average fatigue for the last week scored on 0-100 numerical rating scale where 0 = no fatigue and 100 = the greatest imaginable. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-12.0
Placebo-11.4

Change in the Symptom Checklist 90-Revised (SCL-90R) Somatization Scale Score After 9 Weeks of Treatment

"The SCL-90R Somatization Scale is a 12-item assessment of somatic symptom distress over the past 7 days rated from 0 = not at all to 4 = extremely. The scale score is computed as the mean for all items. The score range is from 0 to 4. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionscore on a scale (Least Squares Mean)
Propranolol ER-0.2
Placebo-0.2

Change in the Weekly Mean Pain Duration After 9 Weeks of Treatment

"Weekly mean pain duration computed as the arithmetic mean of daily pain duration values during the week prior to randomization and prior to each study visit. Daily pain duration is measured on 0-100 percentage scale where percent = percent of waking day you had facial pain as reported in the Daily Symptom Diary. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-17.9
Placebo-16.6

Change in the Weekly Mean Pain Index After 9 Weeks of Treatment

"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary and divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-13.9
Placebo-12.1

Change in the Weekly Mean Pain Intensity After 9 Weeks of Treatment

"Weekly mean pain intensity computed as the arithmetic mean of daily pain intensity values during the week prior to randomization and prior to each study visit. Daily pain intensity is measured on 0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) as reported in the Daily Symptom Diary. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventionunits on a scale (Least Squares Mean)
Propranolol ER-17.1
Placebo-13.6

Change in Thermal Pain Threshold After 9 Weeks of Treatment

Temperature values, measured in degrees Celsius, from 4 examiner-applied contact heat stimuli will be averaged to measure the experimental thermal pain threshold (temperature at which pain is first perceived). The range was 32-50 degrees Celsius and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventiondegrees Celsius (Least Squares Mean)
Propranolol ER1.3
Placebo0.5

Change in Thermal Pain Tolerance After 9 Weeks of Treatment

Temperature values, measured in degrees Celsius, from 4 examiner-applied contact heat stimuli will be averaged to measure the experimental thermal pain tolerance (temperature at which pain can no longer be tolerated). The range was 32-50 degrees Celsius and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

Interventiondegrees Celsius (Least Squares Mean)
Propranolol ER0.5
Placebo0.4

Change in the Weekly Mean Pain Index After 9 Weeks of Treatment Stratified Per Number of COMT LPS Haplotypes

"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary, divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome. The pain index was stratified per number of catechol-O-methyltransferase (COMT) Low Pain Sensitive (LPS) haplotypes." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

,
Interventionunits on a scale (Least Squares Mean)
0 LPS haplotypes1 LPS haplotype2 LPS haplotypes
Placebo-12.3-13.2-2.5
Propranolol ER-14.2-12.2-15.2

Change in the Weekly Mean Pain Index After 9 Weeks of Treatment Stratified Per Number of COMT Valine Alleles at rs4680

"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary, divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome. The pain index was stratified per number of catechol-O-methyltransferase (COMT) valine alleles at single nucleotide polymorphism (SNP) rs4680." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)

,
Interventionunits on a scale (Least Squares Mean)
0 valine alleles1 valine allele2 valine alleles
Placebo-13.9-13.1-9.7
Propranolol ER-14.2-13.9-14.3

Reviews

2 reviews available for propranolol and Ache

ArticleYear
The contribution of autonomic mechanisms to pain in temporomandibular disorders: A narrative review.
    Journal of oral rehabilitation, 2022, Volume: 49, Issue:11

    Topics: Adrenergic Agonists; Analgesics; Antidepressive Agents; Autonomic Nervous System; Botulinum Toxins,

2022
Opioid and catecholaminergic mechanisms of different types of analgesia.
    Annals of the New York Academy of Sciences, 1986, Volume: 467

    Topics: Acetates; Acetic Acid; Acupuncture Therapy; Analgesia; Animals; Electric Stimulation; Electroshock;

1986

Trials

9 trials available for propranolol and Ache

ArticleYear
Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury.
    The Clinical journal of pain, 2015, Volume: 31, Issue:1

    Topics: Adrenergic beta-Antagonists; Adult; Burn Units; Burns; Catechol O-Methyltransferase; Double-Blind Me

2015
Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.
    The journal of pain, 2009, Volume: 10, Issue:5

    Topics: Adrenergic beta-Antagonists; Adult; Cross-Over Studies; Double-Blind Method; Epinephrine; Female; Fi

2009
Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.
    The journal of pain, 2009, Volume: 10, Issue:5

    Topics: Adrenergic beta-Antagonists; Adult; Cross-Over Studies; Double-Blind Method; Epinephrine; Female; Fi

2009
Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.
    The journal of pain, 2009, Volume: 10, Issue:5

    Topics: Adrenergic beta-Antagonists; Adult; Cross-Over Studies; Double-Blind Method; Epinephrine; Female; Fi

2009
Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.
    The journal of pain, 2009, Volume: 10, Issue:5

    Topics: Adrenergic beta-Antagonists; Adult; Cross-Over Studies; Double-Blind Method; Epinephrine; Female; Fi

2009
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M

2010
Effects of intravenous propranolol on heat pain sensitivity in healthy men.
    European journal of pain (London, England), 2013, Volume: 17, Issue:5

    Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Affect; Blood Pressure; Double-Blind Method; Hot Tem

2013
Late exercise test results from a prospective randomized study of bypass surgery for stable angina.
    Circulation, 1983, Volume: 68, Issue:2

    Topics: Adult; Angina Pectoris; Clinical Trials as Topic; Coronary Artery Bypass; Exercise Test; Female; Hum

1983
Effect of propranolol and granisetron on experimentally induced pain and allodynia/hyperalgesia by intramuscular injection of serotonin into the human masseter muscle.
    Pain, 2000, Volume: 84, Issue:2-3

    Topics: Adult; Double-Blind Method; Drug Combinations; Female; Granisetron; Humans; Hyperalgesia; Injections

2000
Influence of CGP 361A, propranolol and diazepam on autonomous reactions to different stressors.
    Progress in neuro-psychopharmacology & biological psychiatry, 1989, Volume: 13, Issue:1-2

    Topics: Adrenergic beta-Antagonists; Adult; Anxiety; Autonomic Nervous System; Blood Pressure; Diazepam; Dou

1989
Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo.
    Acta neurologica Scandinavica, 1986, Volume: 73, Issue:4

    Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders;

1986
Effects of propranolol on the pressor response to noxious stimuli in hypertensive patients.
    The American journal of cardiology, 1968, Volume: 22, Issue:5

    Topics: Adult; Blood Pressure; Cardiac Output; Cold Temperature; Epinephrine; Fatty Acids, Nonesterified; Fe

1968

Other Studies

69 other studies available for propranolol and Ache

ArticleYear
Sex, estrous cycle, and hormone regulation of CYP2D in the brain alters oxycodone metabolism and analgesia.
    Biochemical pharmacology, 2022, Volume: 198

    Topics: Analgesia; Analgesics, Opioid; Animals; Brain; Cytochrome P-450 Enzyme System; Estradiol; Estrous Cy

2022
Recurrent painful ophthalmoplegic neuropathy: a report of two new pediatric cases.
    The Turkish journal of pediatrics, 2022, Volume: 64, Issue:3

    Topics: Child; Child, Preschool; Female; Headache; Humans; Magnetic Resonance Imaging; Ophthalmoplegia; Opht

2022
CYP2D in the brain impacts oral hydrocodone analgesia in vivo.
    Neuropharmacology, 2022, 12-15, Volume: 221

    Topics: Analgesia; Analgesics, Opioid; Animals; Brain; Chromatography, Liquid; Cytochrome P-450 Enzyme Syste

2022
Patients with temporomandibular pain who receive propranolol are more likely to experience pain reduction than those who receive a placebo.
    Journal of the American Dental Association (1939), 2020, Volume: 151, Issue:11

    Topics: Humans; Pain; Propranolol; Somatoform Disorders; Temporomandibular Joint Disorders

2020
A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
    Cephalalgia : an international journal of headache, 2021, Volume: 41, Issue:3

    Topics: Animals; Calcitonin Gene-Related Peptide; Disease Models, Animal; Female; Hyperalgesia; Male; Mice;

2021
Anti-inflammatory effects of propranolol in the temporomandibular joint of female rats and its contribution to antinociceptive action.
    European journal of pain (London, England), 2018, Volume: 22, Issue:3

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Analgesics; Animals; Anti-Inflammatory Ag

2018
Red Ear Syndrome in a Pediatric Patient.
    Pediatric emergency care, 2018, Volume: 34, Issue:10

    Topics: Adrenergic beta-Antagonists; Child; Diagnosis, Differential; Ear Diseases; Ear, External; Erythema;

2018
Propranolol prevents cerebral blood flow changes and pain-related behaviors in migraine model mice.
    Biochemical and biophysical research communications, 2019, 01-08, Volume: 508, Issue:2

    Topics: Adrenergic beta-Antagonists; Animals; Cerebrovascular Circulation; Cortical Spreading Depression; Di

2019
Epinephrine as adjuvant for propranolol produces a marked peripheral action in intensifying and prolonging analgesia in response to local dorsal cutaneous noxious pinprick in rats.
    European journal of pharmacology, 2014, Oct-05, Volume: 740

    Topics: Adjuvants, Pharmaceutic; Analgesia; Anesthetics, Local; Animals; Behavior, Animal; Drug Synergism; E

2014
Catechol-O-methyltransferase inhibition alters pain and anxiety-related volitional behaviors through activation of β-adrenergic receptors in the rat.
    Neuroscience, 2015, Apr-02, Volume: 290

    Topics: Adrenergic Agents; Analgesics; Animals; Anxiety; Catechol O-Methyltransferase; Catechol O-Methyltran

2015
Erythromelalgia with a linear pattern in a 12-year-old girl.
    Pediatrics international : official journal of the Japan Pediatric Society, 2015, Volume: 57, Issue:4

    Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Drug Therapy,

2015
Indirect role of beta2-adrenergic receptors in the mechanism of analgesic action of nonsteroidal antiinflammatory drugs.
    Critical care medicine, 2010, Volume: 38, Issue:9

    Topics: Adrenalectomy; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Analgesics; Animals; Anti-

2010
Effects of epinephrine and cortisol on the analgesic activity of metyrosine in rats.
    Archives of pharmacal research, 2011, Volume: 34, Issue:9

    Topics: Adrenergic beta-Antagonists; alpha-Methyltyrosine; Analgesics; Animals; Carrageenan; Chromatography,

2011
Ventricular arrhythmias triggered by alerting stimuli in conscious rabbits pre-treated with dofetilide.
    Basic research in cardiology, 2004, Volume: 99, Issue:2

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Anti-Arr

2004
Mechanisms involved in the nociception produced by peripheral protein kinase c activation in mice.
    Pain, 2005, Volume: 117, Issue:1-2

    Topics: Adrenergic beta-Antagonists; Analgesics; Animals; Antibodies; Behavior, Animal; Blotting, Western; B

2005
[Effect of emotional pain stress on Na, K-ATPase activity in the myocardium].
    Biulleten' eksperimental'noi biologii i meditsiny, 1982, Volume: 94, Issue:8

    Topics: Adrenergic beta-Antagonists; Animals; Heart; Humans; Male; Myocardium; Pain; Propranolol; Rats; Rats

1982
Should regional anesthesia and pharmacological agents such as beta blockers and opiates be utilized in modulating pain response?
    The Journal of trauma, 1984, Volume: 24, Issue:9 Suppl

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Alfentanil; Analgesia; Analgesics; Anesth

1984
Inhibition of peptidase degrading endogenous opioids: a new trend in the management of migraine and correlated "pain diseases".
    Advances in experimental medicine and biology, 1983, Volume: 156 (Pt B)

    Topics: Brain; Captopril; Clonidine; Cluster Headache; Endorphins; Humans; Migraine Disorders; Nociceptors;

1983
Propranolol disposition after acute myocardial infarction.
    Clinical pharmacology and therapeutics, 1984, Volume: 36, Issue:3

    Topics: Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Hemodynamics; Humans; Injec

1984
[Acute intermittent porphyria].
    Minerva medica, 1983, Nov-10, Volume: 74, Issue:43

    Topics: Acute Disease; Chlorpromazine; Diarrhea; Heme; Hemin; Humans; Intestinal Obstruction; Mitochondria,

1983
The effects of propranolol and amitriptyline on vascular and EMG biofeedback training.
    Headache, 1984, Volume: 24, Issue:2

    Topics: Adolescent; Adult; Aged; Amitriptyline; Biofeedback, Psychology; Female; Humans; Male; Middle Aged;

1984
Phantom limb pain.
    Southern medical journal, 1984, Volume: 77, Issue:6

    Topics: Aged; Humans; Male; Pain; Phantom Limb; Propranolol

1984
Chest pain at exercise and coronary heart disease.
    Acta medica Scandinavica. Supplementum, 1981, Volume: 644

    Topics: Coronary Disease; Exercise Test; Humans; Pain; Practolol; Propranolol; Thorax

1981
Propranolol-induced acute interstitial nephritis.
    The New Zealand medical journal, 1981, Nov-25, Volume: 94, Issue:696

    Topics: Acute Disease; Humans; Male; Middle Aged; Nephritis, Interstitial; Pain; Propranolol

1981
Spontaneously (genetic) hypertensive rats: naloxone-reversible and propranolol-reversible decrease in pain sensitivity.
    Experientia, 1981, Volume: 37, Issue:9

    Topics: Animals; Hypertension; Male; Naloxone; Pain; Propranolol; Rats; Rats, Inbred Strains; Sensory Thresh

1981
Treadmill score quantifies electrocardiographic response to exercise and improves test accuracy and reproducibility.
    Circulation, 1980, Volume: 61, Issue:2

    Topics: Adult; Aged; Arterial Occlusive Diseases; Coronary Disease; Electrocardiography; Exercise Test; Fals

1980
Submaximal exercise testing after unstable angina.
    American heart journal, 1980, Volume: 99, Issue:6

    Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Coronary Disease; Exercise Test; Heart Rate; Humans; M

1980
The opiate antagonist naloxone does not consistently block inhibition of spinal nociceptive transmission produced by stimulation in lateral midbrain reticular formation of the cat.
    Neuroscience letters, 1980, Volume: 20, Issue:3

    Topics: Afferent Pathways; Animals; Cats; Endorphins; Mesencephalon; Naloxone; Pain; Phentolamine; Propranol

1980
Recurrent postpartum painless thyroiditis.
    Southern medical journal, 1980, Volume: 73, Issue:12

    Topics: Adult; Female; Humans; Iodine Radioisotopes; Pain; Pregnancy; Propranolol; Puerperal Disorders; Recu

1980
Silent ST segment deviations and extent of coronary artery disease.
    American heart journal, 1980, Volume: 100, Issue:6 Pt 1

    Topics: Adult; Aged; Cardiac Catheterization; Coronary Disease; Electrocardiography; Female; Heart Rate; Hea

1980
Intravenous propranolol therapy for acute myocardial infarction in man: hemodynamic and serial creatine kinase assessment.
    Chest, 1981, Volume: 79, Issue:3

    Topics: Adult; Aged; Creatine Kinase; Female; Hemodynamics; Humans; Injections, Intravenous; Male; Middle Ag

1981
Rectal response of cardiac origin in the cat: involvement of nitric oxide and acetylcholine.
    European journal of pharmacology, 1997, May-01, Volume: 325, Issue:2-3

    Topics: Acetylcholine; Afferent Pathways; Animals; Arginine; Atropine; Blood Pressure; Cats; Coronary Vessel

1997
Formalin-induced nociceptive behavior and edema: involvement of multiple peripheral 5-hydroxytryptamine receptor subtypes.
    Neuroscience, 1997, Volume: 80, Issue:3

    Topics: Animals; Edema; Formaldehyde; Indoles; Inflammation; Ketanserin; Male; Pain; Propranolol; Rats; Rats

1997
Neural and endocrine mechanisms mediating noxious stimulus-induced inhibition of bradykinin plasma extravasation in the rat.
    The Journal of pharmacology and experimental therapeutics, 1999, Volume: 291, Issue:3

    Topics: Adrenal Glands; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Bradykinin; Caps

1999
Thyrotoxicosis with painless thyroiditis.
    The American journal of medicine, 1976, Volume: 60, Issue:1

    Topics: Adult; Antibodies; Female; Humans; Hyperthyroidism; Male; Middle Aged; Pain; Propranolol; Thyroid Fu

1976
Recurrent chest pain with transient ST-segment elevation and acute myocardial infarction in a patient with normal coronary arteries.
    Canadian Medical Association journal, 1979, Aug-04, Volume: 121, Issue:3

    Topics: Adult; Aspartate Aminotransferases; Coronary Angiography; Creatine Kinase; Electrocardiography; Huma

1979
Carotidynia.
    Neurology, 1977, Volume: 27, Issue:1

    Topics: Adult; Aged; Carotid Artery Diseases; Dose-Response Relationship, Drug; Ergonovine; Female; Headache

1977
Massive propranolol therapy and uncomplicated cardiac surgery.
    JAMA, 1978, Mar-20, Volume: 239, Issue:12

    Topics: Anesthetics; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary Disease; Drug Interaction

1978
Medical management of the patient with unstable angina.
    JAMA, 1978, Feb-27, Volume: 239, Issue:9

    Topics: Angina Pectoris; Diagnosis, Differential; Heart Rate; Humans; Myocardium; Oxygen Consumption; Pain;

1978
The role of aspirin in gastric ulceration . Some factors involved in the development of gastric mucosal damage induced by aspirin in rats exposed to various stress conditions.
    The American journal of digestive diseases, 1978, Volume: 23, Issue:6

    Topics: Animals; Arthritis, Experimental; Aspirin; Atropine Derivatives; Bethanechol Compounds; Cold Tempera

1978
An enzyme mechanism in explanation of pain in angina pectoris.
    Recent advances in studies on cardiac structure and metabolism, 1975, Volume: 10

    Topics: Angina Pectoris; Animals; Bees; Enzyme Activation; Epinephrine; Humans; Nitroglycerin; Norepinephrin

1975
[Differential diagnosis of ischemic heart disease and cardialgia by means of pharmacological tests in the polyclinical practice].
    Kardiologiia, 1977, Volume: 17, Issue:6

    Topics: Adult; Ambulatory Care; Anti-Arrhythmia Agents; Coronary Disease; Diagnosis, Differential; Electroca

1977
Mitral valve prolapse. Recent concepts and observations.
    The American journal of medicine, 1976, Volume: 60, Issue:7

    Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Cardiomyopathies; Coronary Circulation; Coronary Dise

1976
Stress-induced and sympathetically-mediated electrocardiographic and circulatory variations in the primary hyperkinetic heart syndrome.
    Cardiovascular research, 1975, Volume: 9, Issue:3

    Topics: Adolescent; Adult; Atropine; Electrocardiography; Heart Diseases; Hemodynamics; Humans; Isoprotereno

1975
Mechanisms of adrenaline-induced antinociception in mice.
    The Chinese journal of physiology, 1992, Volume: 35, Issue:3

    Topics: Analgesics; Animals; Epinephrine; Injections, Spinal; Male; Mice; Mice, Inbred ICR; Naloxone; Pain;

1992
[Influence of calcium channel blockers and beta-blockers on pain relief with iontophoresis].
    Masui. The Japanese journal of anesthesiology, 1992, Volume: 41, Issue:5

    Topics: Adult; Calcium Channel Blockers; Female; Guanethidine; Humans; Iontophoresis; Lidocaine; Male; Pain;

1992
Inhibition by glutamate antagonists, MK-801 and NBQX, of cutaneo-cardiovascular pain reflex in rats.
    European journal of pharmacology, 1991, Oct-02, Volume: 203, Issue:1

    Topics: Animals; Blood Pressure; Cardiovascular Physiological Phenomena; Cardiovascular System; Dizocilpine

1991
Naloxone-induced hypoalgesia: effects of noradrenergic antagonists and agonist.
    Pharmacology, biochemistry, and behavior, 1991, Volume: 39, Issue:3

    Topics: Animals; Clonidine; Hot Temperature; Male; Naloxone; Norepinephrine; Pain; Prazosin; Propranolol; Ra

1991
Interleukin-8 as a mediator of sympathetic pain.
    British journal of pharmacology, 1991, Volume: 104, Issue:3

    Topics: Animals; Atenolol; Benzazepines; Carrageenan; Dinoprostone; Edema; Foot; Guanethidine; Interleukin-1

1991
Antagonism of stimulation-produced antinociception from ventrolateral pontine sites by intrathecal administration of alpha-adrenergic antagonists and naloxone.
    Brain research, 1990, Oct-15, Volume: 530, Issue:1

    Topics: Adrenergic alpha-Antagonists; Animals; Dioxanes; Dopamine beta-Hydroxylase; Electric Stimulation; Fe

1990
Effects of phentolamine and propranolol on the changes of pain threshold and contents of MEK and LEK in rat brain after EA.
    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 1989, Volume: 9, Issue:3

    Topics: Animals; Brain; Electroacupuncture; Enkephalin, Leucine; Enkephalin, Methionine; Male; Pain; Phentol

1989
A role for histamine and histamine H2-receptors in non-opiate footshock-induced analgesia.
    Life sciences, 1985, Mar-04, Volume: 36, Issue:9

    Topics: Animals; Cimetidine; Electroshock; Haloperidol; Histamine; Histamine H2 Antagonists; Male; Naloxone;

1985
Functional somatic symptoms and hypochondriasis. A survey of empirical studies.
    Archives of general psychiatry, 1985, Volume: 42, Issue:8

    Topics: Anti-Anxiety Agents; Attitude to Health; Benzodiazepines; Conditioning, Psychological; Culture; Diag

1985
The enhancement of the immune response by pain stimulation in mice. I. The enhancement effect on PFC production via sympathetic nervous system in vivo and in vitro.
    Journal of immunology (Baltimore, Md. : 1950), 1987, Jun-01, Volume: 138, Issue:11

    Topics: Animals; Antibody Formation; Epinephrine; Hexamethonium Compounds; Immunoglobulin M; Male; Mice; Osm

1987
Mechanism of peripheral pain in the conscious guinea pig: effect of propranolol.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 1986, Volume: 19, Issue:3

    Topics: Animals; Catecholamines; Evoked Potentials, Somatosensory; Guinea Pigs; Injections, Subcutaneous; No

1986
[Effect of locus coeruleus stimulation on unit discharge of the hypothalamic arcuate nucleus in rats].
    Sheng li xue bao : [Acta physiologica Sinica], 1985, Volume: 37, Issue:2

    Topics: Animals; Arcuate Nucleus of Hypothalamus; Clonidine; Electric Stimulation; Electrophysiology; Hypoth

1985
[Analgesic action of propranolol].
    Yao xue xue bao = Acta pharmaceutica Sinica, 1985, Volume: 20, Issue:9

    Topics: Analgesics; Animals; Clenbuterol; Mice; Pain; Propranolol; Rats; Sensory Thresholds

1985
A surprising cause of abdominal pain, anorexia, vomiting, and weight loss.
    Hospital practice (Office ed.), 1985, Aug-15, Volume: 20, Issue:8

    Topics: Abdomen; Anorexia; Body Weight; Dexamethasone; Diagnosis, Differential; Drug Therapy, Combination; F

1985
Mitral valve prolapse.
    Hospital practice (Office ed.), 1985, Sep-15, Volume: 20, Issue:9

    Topics: Adult; Arrhythmias, Cardiac; Dyspnea; Fatigue; Female; Heart Function Tests; Humans; Male; Mental Di

1985
Role of catecholamines in calcitonin-induced analgesia.
    Pharmacology, 1985, Volume: 31, Issue:6

    Topics: Analgesics; Animals; Atenolol; Calcitonin; Catecholamines; Hydroxydopamines; Injections, Intraventri

1985
[Simultaneous appearance of precordial pain and effort-induced left bundle branch block. A study of 6 patients with normal coronary angiography].
    Archives des maladies du coeur et des vaisseaux, 1985, Volume: 78, Issue:9

    Topics: Adult; Atropine; Bundle-Branch Block; Coronary Angiography; Echocardiography; Exercise Test; Female;

1985
The effect of AH 5158, pindolol, propranolol, D-propranolol on acute exercise tolerance in angina pectoris.
    British journal of pharmacology, 1973, Volume: 47, Issue:3

    Topics: Adrenergic beta-Antagonists; Angina Pectoris; Butylamines; Dose-Response Relationship, Drug; Ethanol

1973
[Qualification of patients with angina pectoris for beta-adrenolytic drug treatment].
    Kardiologia polska, 1974, Volume: 17, Issue:6

    Topics: Adrenergic beta-Antagonists; Angina Pectoris; Coronary Vessels; Humans; Myocardium; Oxygen Consumpti

1974
Catecholamine antagonism to oxytocin-induced milk-ejection.
    Acta endocrinologica. Supplementum, 1971, Volume: 154

    Topics: Adrenergic beta-Antagonists; Angiotensin II; Animals; Blood Pressure; Catecholamines; Epinephrine; F

1971
Role of autonomic nervous system in the pathogenesis of Prinzmetal's variant form of angina.
    Circulation, 1974, Volume: 50, Issue:3

    Topics: Adult; Angina Pectoris; Atropine; Blood Pressure; Coronary Vessels; Electrocardiography; Epinephrine

1974
Clinical, electrocardiographic, and haemodynamic effects of long-term use of propranolol in Prinzmetal's variant angina pectoris.
    British heart journal, 1971, Volume: 33, Issue:6

    Topics: Angina Pectoris; Arteries; Blood Pressure; Electrocardiography; Female; Follow-Up Studies; Heart Rat

1971
A consideration on the mechanism of development of the attack of the variant form of angina pectoris.
    Japanese heart journal, 1970, Volume: 11, Issue:3

    Topics: Adult; Angina Pectoris; Blood Pressure; Catecholamines; Coronary Vessels; Dilatation; Electrocardiog

1970
Exercise-released ventricular fibrillation in hypertrophic subaortic stenosis treated with propranolol. A case report.
    Acta medica Scandinavica, 1970, Volume: 187, Issue:4

    Topics: Adult; Angina Pectoris; Aortic Valve Stenosis; Electrocardiography; Exercise Test; Female; Humans; P

1970
[Symposium on the study of Inderal].
    Kardiologiia, 1967, Volume: 7, Issue:10

    Topics: Angina Pectoris; Arrhythmias, Cardiac; Cardiovascular Diseases; Coronary Disease; Coronary Vessels;

1967